Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women

Menopause

Volumn 19, Issue 8, 2012, Pages 931-941

  Su, Irene H ^a   Chen, Yu Chun ^b   Hwang, Wei Ting ^c   Liu, Ziyue ^c   Su, Tung Ping ^b   Chen, Tzeng Ji ^c   Barnhart, Kurt T ^c   Yang, Yu Xiao ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CHINESE; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EXPOSURE; DRUG FATALITY; ENDOMETRIUM CANCER; FEMALE; HAZARD RATIO; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSE; MYOCARDIAL DISEASE; POSTMENOPAUSE; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; RISK ASSESSMENT; TAIWAN;

EID: 84864281042     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31824362ff     Document Type: Article

References (18)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
3. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-1742.
4. National Center for Health Statistics. United States, 2006 with Chartbook on Trends in the Health of Americans. Hyattsville, MD, 2006.
5. Tannen RL, Weiner MG, Xie D, Barnhart K. A simulation using data from a primary care practice database closely replicated the Women's Health Initiative trial. J Clin Epidemiol 2007;60:686-695.
6. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA 1997;278:89-93.
7. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1998; 148:1195-1205.
8. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-137.
9. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
10. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
11. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
12. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407-1415.
13. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
14. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.
15. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
16. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-242.
17. Zhang X, Shu XO, Li H, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 2005;165:1890-1895.
18. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Maturitas 2005;52:35-51.